Sutro Biopharma, Inc and BioNova Pharmaceuticals Limited announced an option agreement for BioNova to develop and commercialize STRO-001, a CD74-targeting Antibody-Drug Conjugate, for patients with hematologic cancers, in Greater China, including mainland China, Hong Kong, Macau and Taiwan.
[Sutro Biopharma, Inc.]
7992332
{7992332:nan}
apa
50
1
167661
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
